ASH 2022 | Challenges in treating patients with TP53-mutated AML and future outlooks
Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, discusses the difficulties in treating patients with TP53-mutated acute myeloid leukemia (AML), addressing the high relapse rates, poor survival, and the challenge of using measurable residual disease (MRD) to predict patient outcomes. However, Dr Perl highlights that novel agents such as magrolimab and post-transplant maintenance strategies may be able to improve outcomes for these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Astellas, Daiichi Sankyo, AbbVie, Forma, Sumitomo Dainippon, BeatAML LLC: Consultancy; Astellas, Abbvie, Daiichi Sankyo, FujiFilm, Syndax: Research Funding; Astellas, Daiichi Sankyo, Abbvie, Genentech, BerGenBio, Immunogen, BMS/Celgene, Actinium: Membership on an entity’s Board of Directors or advisory committees.
